KALA BIO Executes 1-for-50 Reverse Stock Split to Boost Share Price and Maintain Nasdaq Listing
Summary
KALA BIO, Inc. has officially enacted a 1-for-50 reverse stock split, effective May 8, 2026, to consolidate its outstanding shares and increase its per-share trading price.
Key Events
-
1-for-50 Reverse Stock Split Enacted
KALA BIO, Inc. filed a Certificate of Amendment to its Restated Certificate of Incorporation to effect a 1-for-50 reverse stock split of its common stock. This action was approved by stockholders on January 30, 2026, with the Board determining the 1-for-50 ratio.
-
Effective Date and Trading Impact
The reverse stock split becomes effective at 4:05 p.m. (Delaware time) on May 8, 2026. Common Stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market on May 11, 2026, under the existing 'KALA' symbol.
-
Share Count Reduction
The split will reduce the number of outstanding common shares from approximately 929.5 million to about 18.6 million. The number of authorized shares remains unchanged at 1.5 billion.
-
Fractional Shares and Nasdaq Compliance
No fractional shares will be issued; stockholders entitled to fractional shares will receive a cash payment based on the May 7, 2026 closing price. This move is critical for the company to maintain its Nasdaq listing, especially given prior 'going concern' warnings.
Analysis
KALA BIO's decision to implement a 1-for-50 reverse stock split is a critical move, likely aimed at increasing its per-share price to meet Nasdaq's minimum bid requirements. This action follows a recent 10-K filing that disclosed substantial doubt about the company's ability to continue as a going concern, making the reverse split a necessary step to avoid delisting and potentially enable future financing. While it does not change the company's fundamental valuation, reverse stock splits are generally viewed negatively by the market as they often signal financial distress and historically precede further stock price declines. Investors should monitor the post-split trading performance and any subsequent capital raising efforts.
At the time of this filing, KALA was trading at $0.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $77.2M. The 52-week trading range was $0.08 to $20.60. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.